Moberg Pharma AB (publ) (MOB.ST) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · Sweden · ISIN SE0020353928
Moberg Pharma AB (publ) financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 9.81 m SEK | 13.54 m SEK |
| Gross profit | 6.32 m SEK | 7.68 m SEK |
| Operating income | -324.83 m SEK | -28.00 m SEK |
| EBIT | -320.25 m SEK | -28.00 m SEK |
| Net income | -255.11 m SEK | -27.24 m SEK |
| Diluted EPS – continuing operations | -6.74 SEK | -0.58 SEK |
Full history since 2008, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Moberg Pharma AB (publ)
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It offers MOB-015 for the treatment of nail fungus under the Terclara brand. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. It has license agreement with Karo Healthcare for distribution in European market. Moberg Pharma AB (publ) was incorporated in 2006 and is based in Bromma, Sweden.
More stocks
- Arlitech Electronic (6432.TWO)
- Elton International Trading Company S.A (ELTON.AT)
- Forward Electronics Co., Ltd. (8085.TWO)
- Budi Starch & Sweetener Tbk (BUDI.JK)
- Single Well Industrial (3490.TWO)
- TROPHY GAMES Development AS (TGAMES.CO)
- Springvest Oyj (SPRING.HE)
- PT Segar Kumala Indonesia Tbk (BUAH.JK)
- Starfighters Space, Inc. (FJET)
- Yoong Onn Corporation Bhd (5159.KL)
- Solid Year Co., Ltd. (6737.TWO)
- First Southern Bank (FSBH)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.